News and Trends 18 Sep 2017 German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed in Europe. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Cyltezo for approval, moving it closer to the market and offering a new treatment for a range of inflammatory diseases. The biosimilar drug of adalimumab (Humira) could treat […] September 18, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2017 British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial Allergy Therapeutics’ vaccine against hayfever has received approval to begin a trial to determine its optimal dose. Allergy Therapeutics will begin a Phase II trial of its PQ Grass vaccine for grass pollen-induced allergic rhinitis imminently. A major selling point for PQ Grass is its ultra-short course, which reduces treatment time from 1 year to […] September 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2017 Update: After 25 years, MorphoSys Gets its First Antibody Approved Update (19/09/2017): Janssen has received a positive CHMP opinion recommending the approval of Tremfya (guselkumab) in Europe for moderate to severe plaque psoriasis. The approval could make Tremfya the first antibody developed by MorphoSys to hit the European market, just a few months after its US approval. Originally published on 14/07/2017 Janssen has received FDA approval for Tremfya […] September 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2017 How Does it Feel Like to be a Slime Mold in Berlin? Bioartist Heather Barnett explores the amusing world of a microorganism that can navigate its way around cities much like a human would do. Physarum polycephalum, commonly known as slime mold, is a fascinating microorganism. This yellow single-celled being has no brain or nervous system, but it can play piano and write Hebrew. It can also […] September 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2017 New British Biotech Enters the Clinic with Opioid Alternative for Chronic Pain Levicept’s Phase I study will test their new pain relief candidate’s safety and tolerability in healthy individuals and osteoarthritis patients. Levicept, based in Sandwich, UK, focuses on the development of its pain relief candidate, LEVI-04, a p75 neurotrophin receptor fusion protein (p75NTR-Fc). The Phase I study is the company’s maiden voyage into the clinic, and it will test the […] September 15, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2017 Swiss-US Partners Reveal New Candidate for Autoimmune Disease Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to develop a new form of treatment for diabetes, obesity and autoimmune diseases. After initial research, the team has now selected its first candidate for clinical […] September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2017 Bayer Launches Plant Microbiome Biotech with a Huge €84M Series A Bayer and Ginkgo Bioworks are launching a new company that will develop new technologies for sustainable agriculture by engineering the plant microbiome. With the microbiome already gaining traction in the therapeutics field, Bayer has decided to take it to agriculture. In partnership with US synthetic biology upstart Ginkgo Bioworks, the German giant is creating a new […] September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 A Swedish-Spanish Team Takes on a New Immuno-Oncology Target Alligator Bioscience will collaborate with the University of Navarra, Spain, to study the potential of CD137 as a target for new cancer immunotherapies. Alligator Bioscience, based in Lund, Sweden, has teamed up with Prof. Ignacio Melero at the Center for Applied Medical Research (CIMA) at the University of Navarra to study the biological effects of activating […] September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 Italian Biotech Closes €7M Series B for Stem Cells to Treat Cancer Genenta Science has raised $8M (€7M) in the Series B fundraising round to continue investigating its use of hematopoietic stem cells to treat cancer. Based in Milan, Genenta can add €7M to the €10M secured in Series A of fundraising. Italian, British and Swiss private investors led the investment, and it will allow the biotech to start a second […] September 13, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 Epigenetics Drug Proves Effective in Phase I for Lethal Cancer 4SC’s partner Yakult Honsha has presented positive results at ESMO 2017 for the epigenetics drug resminostat in a Phase I trial run in Japan. The histone deacetylase (HDAC) inhibitor resminostat has shown to induce tumor shrinkage or disease stabilization in all patients with biliary tract cancer in a Phase I trial. The goal was to determine […] September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 Series D Boost will Bring Artificial Intelligence to Diagnostics Worldwide Sophia Genetics has raised $30M (€25M) in Series D that will be directed to growing and improving its artificial intelligence platform for genetic diagnostics. The Swiss company Sophia Genetics has announced today a new round of funding, led by Balderton Capital, and joined by 360º Capital Partners and existing investors Invoke Capital and Alychlo. The […] September 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 What You Need to Know About the EU’s New Data Protection Law The EU’s new data protection law is going to have a great impact on companies worldwide, including those involved in clinical trials. Here’s what you have to know and how to act! In May 2018, the European Union’s new data protection law, the General Data Protection Regulation (GDPR), is set to replace the current Data […] September 13, 2017 - 13 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email